

FAKULTNÍ NEMOCNICE PLZEŇ
I. INTERNÍ KLINIKA

BIOMEDICÍNSKÉ CENTRUM

KDY INDIKUJI RRT U INTOXIKACÍ

Jaroslav Raděj
XIII. KONGRES ČESKÉ SPOLEČNOSTI INTERNÍ MEDICÍNY 24. - 26. dubna 2019 v Praze

1

2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report

Table 1A. AAPCC population served and reported exposures (1983-2017).

Year	No. of participating centers	Population served (in millions)	Human exposures	Exposures per thousand population
2015	55 ^a	325.4 ^b	2,168,371	6.7
2016	55	327.0 ^c	2,159,032	6.6
2017	55	330.4 ^d	2,115,186	6.4

Table 1B. Substance category. Table 1C. Substance categories most frequently identified in drug identification calls (Top 25).

Substance (Major Generic Category)	All substances	% ^a	cases	% ^b
Analgesics	38,765	33.78	835	54.1
Sedative-Hypnotics/Anesthetics	20,449	17.82	442	38.6
Cardiovascular Drugs	8,271	7.21	767	48.2
Cleaning Substances (Household)	6,916	6.03	159	22.7
Alcohol	5,704	4.97	159	22.7
Unknown Drug	5,069	4.42	159	22.7
Cardiovascular Drugs	4,919	4.29	159	22.7
Antidepressants				
Muscle Relaxants				
Anticonvulsants				

DD Gummin. Clinical Toxicology, 2018

2


2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report

Therapy	n by age					Total
	6-12 y	13-19 y	>=20 y	Unknown child	Unknown adult	
Hemodialysis	15	2,487	2	5	0	2,629
Hemoperfusion	8	141	0	0	0	38
Extracorp. procedure (other)						154


hemodialýza v 0,12% případů

DD Gummin. Clinical Toxicology, 2018


3




4



5



6



7

ACETYSALICYLIC ACID INTOXICATION
A PROPOSED METHOD OF TREATMENT
Lieutenant (jg) Paul D. Doolan, Medical Corps, United States Navy,
William F. Walsh, M.D., Lawrence H. Kujala, M.D.,
and Henry Winklesky, M.S., Washington, D. C.

Facilities resulting from acetylsalicylic acid (aspirin) intoxication are state, but when sufficient amounts are taken the drug is an effective analgesic agent. The exact lethal dose is unknown, but death has followed doses of as little as 2 Gm. However, adults must ordinarily ingest 15 to 30 Gm. before a fatality will ensue. Salicylates induce pathological lesions of an irreversible nature in the central nervous system, and treatment, in the absence of a specific antidote, depends on rapid removal from the body. Normally, the kidney is the chief route of excretion. When minimal amounts are ingested, severe renal impairment may occur, and this complication, or the presence of antecedent renal disease imposes formidable obstacles to treatment.

REPORT OF A CASE

A 39 year old white male was first admitted, as a victim, to another hospital at 6:45 p. m. He was treated from his wife that he had consumed that night 10 to 15 Gm. acetylsalicylic acid tablets that day, in addition to an unknown quantity during the preceding 24 hours. He was discharged with prescription. The prescription, although only 20 per cent, were extremely drug. The amount ingested was estimated at the 100 mg. per cent point to eight. The prescription dose was 1.5 mg. per cent per cent per cent. Because of the patient's medical condition, he was transferred to Georgetown University Hospital for treatment with the artificial kidney. He arrived at the hospital about 11 p. m. on the same day. His condition remaining unchanged except for extreme restlessness. Lumbar puncture revealed clear fluid, and the electroencephalogram did not show any changes suggestive of alkalosis. He was given dialysis in water, ascorbic acid and vitamin K could be added before the artificial kidney was used. Clinical condition gradually improved with the dialysis because of the patient's restlessness, and the procedure had to be terminated at the end of one hour. Barbiturates and paraldehyde were used in very small doses, since sedatives have been reported to potentiate the toxic effects of the salicylate on the central nervous system. His condition remained critical, slight respiratory apparatus, and that at 7 a. m. on the following day, respiratory failure. Neuropraxia, dislocated patellar hemiparesis, convulsions, and convulsions, from time, showed persistent and steadily. Promptly after death, the patient's death revealed that he had been consuming acetylsalicylic acid tablets by the method of Koller with slight modifications. Signs and symptoms of salicylation had appeared three days prior to admission, when he began to complain of nausea, vomiting, tinnitus and deafness.

It is a fact that only one hour of dialysis was accomplished. 2.50 mg. of acetylsalicylic acid were removed in the bath, the blood containing 55 mg. per 100 cc. Consequently, further use of the procedure appeared worth while. Salicylates were determined by the method of Koller with slight modifications. The type of artificial kidney used was a modified Koff model's.

Presented in part before the Southern Section of the American Pediatric Society, the Department of Medicine, Georgetown University, Howard and Georgetown University School of Medicine, Washington, D. C., July 1951. Reprinted from the Journal of the American Medical Association, Vol. 137, No. 1, p. 10, 1951. Copyright, 1951, by the American Medical Association. Reprinted by permission of the American Medical Association, New England J. Med. 243: 124, 1950.

1. A. K. Koff, M.D., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

2. G. Winklesky, M.S., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

3. G. Winklesky, M.S., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

4. G. Winklesky, M.S., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

5. G. Winklesky, M.S., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

6. G. Winklesky, M.S., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

7. G. Winklesky, M.S., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

8. G. Winklesky, M.S., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

9. G. Winklesky, M.S., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

10. G. Winklesky, M.S., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

11. G. Winklesky, M.S., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

12. G. Winklesky, M.S., and H. Winklesky, M.S., Acetylsalicylic Acid Poisoning, with a Review of the Literature, *Journal of the American Medical Association*, Vol. 137, No. 1, p. 10, 1951.

PD Doolan, JAMA, 1951

8

Benefit vs. riziko ECTR u intoxikace

George E. Schreiner

- zavazny prubeh intoxikace
- intoxikace je vysoce rizikova absorbovanym mnozstvym toxinu
- absence mozneho ucinného konzervativniho postupu nebo antidota
- Zejména je metoda ECTR indikována, pokud se zdravotní stav pacienta zhoršuje přes vyčerpaná podpůrná a konzervativní opatření.
- predpoklad ucinného zvyšeni eliminace noxy
- V ideálním případě nízká endogenní clearance toxinu vs. vysoká účinnost eliminace extrakorporální metodou.
- poskozen přirozený mechanismus eliminace toxické látky

9

Benefit vs. riziko hemodialýzy u intoxikace

- zavazny prubeh intoxikace, zejména spatne reagujici na podpurna a konzervativni opatreni
- intoxikace je vysoce rizikova absorbovanym mnozstvym toxinu
- absence mozneho ucinného konzervativniho postupu nebo antidota
- zkraceni doby nutných podpurných opatreni, monitorace, lecbý antidotem
- predpoklad ucinné difuze semipermeabilni membránou: high-flux high-efficiency dialyzer (M₁ 10,450D): 80 % I/kg; PBP < 80 %
- poskozeni funkce ledvin
- tezká metabolická acidóza, iontové poruchy, hyperhydratace

10

hemodialýza je indikována u závažné intoxikace:

alkoholy a glykoly; lithium; metformin; salicylová kyselina; theofylin; valproová kyselina

hemodialýza může být použita u závažné intoxikace:

acetbutolol; antimikrobiální léky (některé); atenolol; baklofen; barium; boritá kyselina; bromidy; cyklofosfamid; dabigatran; dapson; fenobarbital; fenytoin; gabapentin; chloralhydrát; jod; kalcium; kalium; karbamazepin; lisinopril; magnézium; meprobamat; methotrexat; mexicilin; nadolol; paracetamol; pregabalin; primidon; prokainamid; sotalol; těžké kovy a jejich chelátové komplexy

11

EXTRIP
 Blood Purification in Toxicology/Reviewing the Evidence and Providing Recommendations

OBJECTIVE PUBLICIZING RECOMMENDATIONS NEWS EVENTS METHODS REPRESENTED SOCIETIES

REPRESENTED SOCIETIES

American Academy of Clinical Toxicology
 American College of Emergency Physicians
 American College of Medical Toxicology
 American Society of Nephrology
 American Society of Pediatric Nephrology
 Asia Pacific Association of Medical Toxicology
 Australian and New Zealand Intensive Care Society
 Australian and New Zealand Society of Nephrology
 Brazilian Association of Intensive Care and Toxicologic Assistance
 Brazilian Society of Nephrology
 Brazilian Society of Toxicology
 Canadian Association of Poison Control Centres
 Canadian Association of Emergency Physicians
 Canadian Society of Nephrology
 Chinese College of Emergency Physicians
 Chinese Medical Doctor Association
 European Association of Poison Centres and Clinical Toxicologists
 European Renal Best Practice
 European Society of Emergency Medicine
 European Society of Intensive Care Medicine
 French Language Society of Resuscitation
 German Society of Nephrology
 International Pediatric Nephrology Association
 International Society of Nephrology
 Latin American Society of Nephrology and Hypertension
 National Kidney Foundation
 Pediatric Continuous Renal Replacement Therapy
 Pediatric Critical Care Medicine
 Quebec Association of Emergency Physicians
 Quebec Association of Specialists in Emergency Medicine
 Quebec Society of Nephrology
 Renal Association
 Society of Critical Care Medicine
 Spanish Clinical Toxicology Foundation

EXTRIP, The Extracorporeal Treatments In Poisoning workgroup
www.extrip-workgroup.org

12

Table 7. Summary of the effect for dialyzability.

Dialyzability ⁶	Primary criteria % Removed ^a	Alternative criteria 1 Cl ₁₀₀ CL ₁₀₀ (%) ^b	Alternative criteria 2 T _{1/2} EC _{1/2} (%)	Alternative criteria 3 Re _{EC} Re ₁₀₀ (%) ^c
D, Dialyzable	>30	>75	<25	>75
M, Moderately dialyzable	>10 – 30	>50 – 75	>25 – 50	>50 – 75
S, Slightly dialyzable	≥3 – 10	≥25 – 50	≥50 – 75	≥25 – 50
N, Not dialyzable	<3	<25	>75	<25

These criteria should only be applied if measured or calculated (not reported) endogenous half-life is > 4hours (otherwise, ECTR is considered not clinically relevant). Furthermore, the primary criteria is preferred for poisons having a large Vd (> 5L/Kg).

^aApplicable to all modalities of ECTR, including hemodialysis, hemoperfusion, hemofiltration.

^bCorresponds to % removal of ingested dose or total body burden in a 6-hour ECTR period.

^cMeasured during the same period of time.

Type of statements for proposal:

- Toxicokinetic statement:** Poison X is (Dialyzable, Moderately dialyzable, Slightly dialyzable, Not dialyzable) by ECTR (GRADE equivalent). EXAMPLE: Salicylates are moderately dialyzable by ECTR (A).
- General statement:** (We recommend/ We suggest/ it would be reasonable/ no agreement reached) to (perform/not perform) ECTR in severe poisoning with "X" (GRADE). EXAMPLE: We recommend performing ECTR in severe salicylate poisoning (1D).
- Specific statements:** If there is support for performing ECTR, other statements (with grade) will be submitted; indications of initiating ECTR (ingestion, level, special population, symptoms, clinical markers), when to discontinue ECTR, preferable ECTR modality, particularities of ECTR with the particular poison (timing, special population, technical).

V Lavergne. Clin Toxicol (Phila), 2012

13

EXTRIP
Blood Purification in Toxicology: Reviewing the Evidence and Providing Recommendations

OBJECTIVES | PUBLICATIONS | RECOMMENDATIONS | NEWS & EVENTS | INFORMANTS | REFERENCED SOCIETIES

EXECUTIVE SUMMARY OF RECOMMENDATIONS

SALICYLATES POISONING

General Recommendation

- ECTR is recommended in severe salicylate poisoning (1D)

Indications

- ECTR is recommended in all of the following are met:
 - Plasma level > 2.0 mmol/L (30 mg/dL) (1D)
 - Plasma level > 1.0 mmol/L (15 mg/dL) in the presence of impaired kidney function (1D)
 - In the presence of altered mental status (1D)
 - In the presence of hemoptysis requiring supplemental oxygen (1D)

Standard therapy (supportive measures, bicarbonates, etc.) (1D). ECTR is suggested if any of the following are met:

- Plasma level > 0.5 mmol/L (7.5 mg/dL) (2D)
- Plasma level > 0.5 mmol/L (7.5 mg/dL) in the presence of impaired kidney function (2D)
- If the systemic pH is < 7.30 (2D)

Contraindications of ECTR in salicylate if:

- renal impairment to support (1D) and
- Diarrhea (> 4 a month, 10 mg/kg, 1D) or ECTR has been performed for a period of at least 4-6 h when salicylate concentrations are not readily measure (2D)

Choice of ECTR

- is preferred in the patient not readily in patients with multiple poisoning (1D)
- The following are acceptable alternatives if HD is not available:
 - HF (2D)
 - CRRT (2D)
 - Exchange transfusion in neonates (1D)
- Miscellaneous: It is recommended to contrast intravenous bicarbonate therapy between ECTR sessions (1D)

Lithium
Salicylates
Thallium
Theophylline
Valproic Acid

14

EXTRIP
Blood Purification in Toxicology: Reviewing the Evidence and Providing Recommendations

OBJECTIVES | PUBLICATIONS | RECOMMENDATIONS | NEWS & EVENTS | INFORMANTS | REFERENCED SOCIETIES

EXECUTIVE SUMMARY OF RECOMMENDATIONS

SUBSTANCES

Acetaminophen	Phenytoin
Barbiturates	Salicylates
Carbamazepine	Thallium
Digoxin	Theophylline
Lithium	Tricyclic Antidepressants
Metformin	Valproic Acid
Methanol	


GRADE A až D (vysoká až velmi nízká úroveň evidence)
síla konsenzuálního doporučení: 1= silné doporučení (doporučuji...)
2= slabé doporučení (navrhuji...)
3= neutrální doporučení (bylo by rozumné...)

15

zvýšený osmolální gap	metabolická acidóza se zvýšeným anion gapem
dietylglykol → ADH → 2-hydroxy-ethyls-pyruvát-dehyd → ALDH → kyselina 2-hydroxyvetvoctová/HE acetiát	→ kyselina dikolková/dietykolát
etylglykol → ADH → glykolaldehyd → ALDH → kyselina glykolová/glykolát	→ kyselina glyoxalová/glyoxalát
metanol → ADH → formalddehyd → ALDH → kyselina mravčí/oxalát	→ kyselina mravčí/oxalát
propylyglykol → ADH → laktaldehyd → ALDH → kyselina mléčná/laktát	→ kyselina pyruvová/pyruvát

ADH alkoholdehydrogenáza, ALDH aldehyddehydrogenáza

16




17

Intermittentní hemodialýza vs. CVVHD

IHD	CVVHD (CRRT)
<ul style="list-style-type: none"> účinnější clearance noxy rychlejší korekce vnitř. prostředí 	<ul style="list-style-type: none"> lepší hemodynamická tolerance? vs. 4,8 l/hod
<p>Q_d 30 l/hod</p> <ul style="list-style-type: none"> kratší doba antikoagulace, popř. proplachy mimočlňního okruhu kratší doba nutné monitorace vnitř. prostředí, imobilizace,... 3-4x nižší cena 	<p>Co je významná hemodynamická nestabilita? překles TK 10-70% při IHD; 40-60% při SLED; do 50% při CRRT</p>
<ul style="list-style-type: none"> isovolemičké napojení start s nižším krátkem krve D-Na ≥ 145 mmol/l, modelování nižší teplota dialyzátu (start např. 36 °C) vyřazení netto ultrafiltrace bikarbonátový roztok 	

A Dauvins. Crit Care, 2018
F Schortgen. Am J Respir Crit Care Med, 2000

18



19

Metformin-associated lactic acidosis, MALA Metformin-induced lactic acidosis, MILA

Endogenní clearance metforminu při normální funkci ledvin je 500-600 ml/min.

- ✓ eliminace kumulovaného léku/toxinu a korekce vnitřního prostředí
- dávka ECTR vs. hemodynamická nestabilita (IHD, SLED, CRRT)
- ✓ dávka ECTR vs. riziko disekvilibría (hypertenze při alkalizaci, zvýšení D-Na)
- ✓ intolerance citrátové antikoagulaace je pravděpodobná

Nephrol Dial Transplant. 2004 Aug;19(8):2157-8.
Combination of intermittent haemodialysis and high-volume continuous haemofiltration for the treatment of severe metformin-induced lactic acidosis.
Panzer U, Kluge S, Kreymann G, Wolf G.

Nephrol Dial Transplant. 2006 Jul;21(7):2038-9. Epub 2006 Jan 31.
Combined renal replacement therapy for severe metformin-induced lactic acidosis.
Friesicke S, Abel P, Kraft M, Gerner A, Runge S.

20

Hemoperfuze na ústupu

- ✓ M_r 5-10 kDa; PPB < 90 %; lipofilní
- ✓ extrakční poměr mnohdy = 1, CL až rovná Q_c
- ✓ NÚÚ: trombocytopenie, leukopenie, hypokalcemie, hypofosfatemie, hypoglykemie, hypofibrinogenemie a koagulopatie
- ✓ při Q_c nad 350 ml/min hrozí hemolýza
- ✓ vyšší nároky na antikoagulaaci
- ✓ saturace adsorbentu á 2-4 hodin s nutnou výměnou
- ✓ cena 10x vyšší než IHD
- ✓ nemožnost korekce vnitřního prostředí a volémie
- ✓ klesající zkušenosti

nepoužívaná nedostupná

21

EXTRIP

Blood Purification in Toxicology/Reviewing the Evidence and Providing Recommendations

ACETAMINOPHEN (APAP) POISONING

General Recommendation

- ECTR is suggested in severe APAP poisoning (2E)

Indications

ECTR is recommended

- if the [APAP] more than 1000 mg/L (6820 µmol/L) and NAC is NOT administered (1D)
- if the patient presents with altered mental status, metabolic acidosis, with an elevated lactate, and an [APAP] is more than 700 mg/L (4620 µmol/L) and NAC is NOT administered (1D)
- if the patient presents with an altered mental status, metabolic acidosis, an elevated lactate, and an [APAP] is more than 900 mg/L (5980 µmol/L) even if NAC is administered (1D)
- based on the rates of the primary or new or administered (1D)

Cessation of ECTR

- ECTR is recommended until sustained clinical improvement is apparent (1D)

Choice of ECTR

- Intermittent hemodialysis is the preferred ECTR in patients with APAP poisoning (1D)
- The following are acceptable alternatives if HD is not available:
 - Intermittent HF (1C)
 - CRRT (2D)

Miscellaneous

- NAC therapy should be continued during ECTR at an increased rate (1D)

22

Shrnutí

- ✓ Léčíme pacienta, ne jed.
- ✓ ECTR indikují podle klinického vývoje a reakce na léčbu, nebo ve snaze předjet katastrofickému vývoji.
- ✓ Pro efekt správné indikované ECTR u intoxikace je rozhodující dávka metody.
- ✓ V nasazení dominuje IHD, podle dostupnosti metody a zkušenosti.
- ✓ Hemodynamická nestabilita není absolutní kontraindikací IHD.
- ✓ Absence toxikinetických předpokladů noxy ještě nevylučuje úspěšné zvýšení eliminace metodou IHD při masivní intoxikaci.

Toxikologické informační středisko (TIS) Kliniky pracovního lékařství VFN a 1. LF UK v Praze

EXTRIP, www.extrip-workgroup.org

Program rozvoje vědních oborů Univerzity Karlovy (Progres - projekt Q39)
Národní program udržitelnosti 1 (NPU I) č. LO1503 poskytnutý Ministerstvem školství, mládeže a tělovýchovy

23